Current Practice in Diagnosis and Treatment of Growth Hormone Deficiency in Childhood: A Survey from Turkey
Authors:
- Şükran PoyrazoğluŞPŞükran Poyrazoğlu
- Teoman AkçayTATeoman Akçay
- İlknur ArslanoğluİAİlknur Arslanoğlu
- Mehmet Emre AtabekMAMehmet Emre Atabek
- Zeynep AtayZAZeynep Atay
- Merih BerberoğluMBMerih Berberoğlu
- Abdullah BereketABAbdullah Bereket
- Aysun BideciABAysun Bideci
- İfFet BircanIBİfFet Bircan
- Ece BöberEBEce Böber
- Şule CanŞCŞule Can
- Yaşar CesurYCYaşar Cesur
Open Access
- 5 March 2015
- journal article
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 7 (1) , 37-44
Abstract
Approaches to diagnosis and treatment of growth hormone deficiency (GHD) in children vary among countries and even among centers in the same country. This survey, aiming to facilitate the process of preparing the new consensus on GHD by the Turkish Pediatric Endocrinology and Diabetes Society, was designed to evaluate the current practices in diagnosis and treatment of GHD in different centers in Turkey. A questionnaire covering relevant items for diagnosis and treatment of GHD was sent out to all pediatric endocrinology centers. Twenty-four centers returned the questionnaire. The most frequently used GH stimulation test was L-dopa, followed by clonidine. Eighteen centers used a GH cut-off value of 10 ng/mL for the diagnosis of GHD; this value was 7 ng/mL in 4 centers and 5 ng/mL in 2 centers. The most frequently used assay was immunochemiluminescence for determination of GH, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 concentrations. Sex steroid priming in both sexes was used by 19 centers. The most frequently used starting dose of recombinant human GH (rhGH) in prepubertal children was 0.025-0.030 mg/kg/day and 0.030-0.035 mg/kg/day in pubertal children. Growth velocity was used in the evaluation for growth response to rhGH therapy in all centers. Anthropometric measurements of patients every 3-6 months, fasting blood glucose, bone age and thyroid panel evaluation were used by all centers at follow-up. Main indications for cessation of therapy were decreased height velocity and advanced bone age. Fourteen centers used combined treatment (rhGH and gonadotropin-releasing analogues) to increase final height. Although conformity was found among centers in Turkey in current practice, it is very important to update guideline statements and to modify, if needed, the approach to GHD over time in accordance with new evidence-based clinical studies.Keywords
This publication has 27 references indexed in Scilit:
- Growth hormone deficiency in childrenPituitary, 2008
- Variation in Growth Hormone Immunoassays in Clinical Practice in CanadaHormone Research in Paediatrics, 2008
- Is growth hormone stimulation testing in children still appropriate?Growth Hormone & IGF Research, 2004
- Estrogen Priming Effect on Growth Hormone (GH) Provocative Test: A Useful Tool for the Diagnosis of GH Deficiency1The Journal of Clinical Endocrinology & Metabolism, 2000
- Growth Hormone Testing and the Short ChildPediatric Research, 2000
- Diagnosis and Treatment of Growth Hormone Deficiency in Children and Adolescents: Towards a ConsensusHormone Research in Paediatrics, 1998
- Guidelines for the use of growth hormone in children with short stature A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine SocietyaThe Journal of Pediatrics, 1995
- Survey of growth hormone treatment practices by 251 pediatric endocrinologists.The Journal of Clinical Endocrinology & Metabolism, 1995
- Intrasubject reproducibility of growth hormone-releasing hormone-stimulated growth hormone in older women, older men, and younger menBiological Psychiatry, 1993
- What is a normal stimulated growth hormone concentration?Journal of Endocrinology, 1992